Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Aug. 23, 2025 (GLOBE NEW ...

Core Viewpoint - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. for allegedly misleading investors regarding the quality of care provided at its facilities and undisclosed risks associated with child abuse incidents [3][4]. Company Overview - KinderCare Learning Companies, Inc. (NYSE: KLC) is facing legal action in the United States District Court District of Oregon on behalf of investors who purchased its IPOs [1]. - The lawsuit claims that the registration statement for the IPO was false and/or misleading, failing to disclose significant issues related to child care quality and safety [3]. Allegations - The lawsuit alleges that numerous incidents of child abuse, neglect, and harm occurred at KinderCare facilities [3]. - It is claimed that KinderCare did not provide the "highest quality care possible" and failed to meet basic standards in the child care industry [3]. - The company is accused of being exposed to material risks, including lawsuits, regulatory actions, and reputational damage due to these undisclosed issues [3]. Stock Performance - Since the IPO, KinderCare's stock price has fallen to lows near $9 per share, indicating a significant decline in investor confidence [4].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Sarepta securities between June 22, 2023, and June 24, 2025 [1]. - Investors have until August 25, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Sarepta - Sarepta is accused of making materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with a positive revenue outlook [3]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to recruitment halts and regulatory scrutiny [3]. Group 3: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock fell by $27.81 (27.44%) to close at $73.54 [4]. - After the announcement on April 4, 2025, regarding regulatory scrutiny, the stock dropped by $4.18 (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, led to a further decline of $15.24 (42.12%) to close at $20.91 [4]. - The FDA's Safety Communication on June 24, 2025, resulted in a stock price decrease of $1.52 (8.01%) to close at $17.46 [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint specifies that Hims failed to disclose that its communication with Novo Nordisk was not as beneficial as portrayed, potentially jeopardizing the long-term collaboration for access to Wegovy [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk, which could mislead investors about the company's product offerings [4]. - The lawsuit highlights that Hims made false statements regarding the availability of branded Wegovy alongside its compounded products, which could mislead users and investors about the company's market position [4].

Core Viewpoint - A class action lawsuit has been filed against Vestis Corporation for allegedly providing misleading information to investors regarding its business growth and strategic initiatives [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Vestis securities between May 2, 2024, and May 6, 2025, with a deadline of August 8, 2025, to apply as lead plaintiff [1]. - The complaint alleges that Vestis made overwhelmingly positive statements while concealing material adverse facts about its business growth capabilities [3]. Group 2: Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrawing its revenue and growth guidance for the full fiscal year [4]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in customer volume [4]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Laser Photonics Corporation for possible violations of federal securities laws and unlawful business practices [1][3]. Financial Disclosure Issues - On September 23, 2024, Laser Photonics announced that its previously issued financial statements for the year ended December 31, 2023, and the quarter ended June 30, 2024, should no longer be relied upon due to an overstatement of deferred revenue identified by its predecessor auditor, Fruci & Associates II, PLLC [3]. - Following this announcement, Laser Photonics' stock price dropped by $6.90 per share, or 36.7%, closing at $11.90 per share on September 25, 2024 [3]. Legal Rights and Investor Support - Investors who purchased or acquired Laser Photonics shares and suffered losses are encouraged to contact Bragar Eagel & Squire for information regarding their legal rights and potential claims [1][4].

Core Viewpoint - A class action lawsuit has been filed against Krispy Kreme, alleging that the company made false statements regarding its partnership with McDonald's and the demand for its products, leading to significant financial losses for investors [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Krispy Kreme securities between March 26, 2024, and May 7, 2025 [1]. - Investors have until July 15, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. - The lawsuit claims that demand for Krispy Kreme products declined significantly at McDonald's locations after the initial marketing launch [3]. Group 2: Financial Performance - Krispy Kreme reported net revenue of $375.2 million for the first quarter of 2025, representing a decline of 15.3% compared to the previous year [4]. - The company also reported a net loss of $33.4 million, compared to a net loss of $6.7 million in the prior year [4]. - Following the release of these financial results, Krispy Kreme's share price fell by nearly 25% [4]. Group 3: Partnership with McDonald's - Krispy Kreme and McDonald's expanded their partnership nationwide starting in the second half of 2024, following a small-scale test in 2022 [2]. - The lawsuit alleges that the partnership was not profitable and posed a substantial risk to maintaining the collaboration with McDonald's [3]. - Krispy Kreme announced it is reassessing its deployment schedule with McDonald's and has withdrawn its prior full-year outlook due to uncertainty around the partnership [4].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of Indiana on behalf of individuals and entities that purchased Elevance securities between April 18, 2024, and October 16, 2024 [1]. - Investors have until July 11, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Elevance - Defendants allegedly misrepresented their monitoring of cost trends related to the Medicaid redetermination process and assured investors that premium rates were sufficient to manage risks associated with Medicaid patients [3]. - The lawsuit claims that while Medicaid expenses were acknowledged to be rising, the true impact of the redetermination process was not adequately reflected in Elevance's financial guidance for 2024 [3]. - It is asserted that the acuity and utilization of Medicaid members increased significantly, as those removed from Medicaid were generally healthier than those who remained eligible [3]. Impact on Investors - The lawsuit contends that when the true details regarding the Medicaid redetermination process became public, investors suffered damages due to the misleading statements made by Elevance [3].